ADR (QNRX) stock price has shown some volatility, fluctuating -40.30% over the last five trades and -34.67% over the past 30 trades. This represents a notable shift from earlier in the year. Over the ...
After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured ...
Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report) and keeping the price target at ...
ASHBURN, Va., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty ...
Quoin Pharmaceuticals (QNRX) announces further clinical evidence of the potential efficacy of QRX003 in Netherton Syndrome. In December 2024 ...
ADR (QNRX) stock price has shown some volatility, fluctuating -35.40% over the last five trades and -33.06% over the past 30 trades. This represents a notable shift from earlier in the year. Over the ...
Jan. 23, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan ...
Quoin Pharmaceuticals has announced new clinical data indicating the need for ongoing treatment with QRX003 for patients with Netherton Syndrome, as all positive effects observed during a 12-week ...
(RTTNews) - Quoin Pharmaceuticals, Inc. (QNRX), a clinical-stage specialty pharmaceutical company, on Thursday, announced additional clinical data supporting the efficacy of its investigational ...
Jan. 23, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases ...